Clinical Trial Update: HPV-E6-Specific Anti-PD1 TCR-T Cells in the Treatment of HPV-Positive NHSCC or Cervical Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial of HPV-E6-specific anti-PD1 TCR-T cells for HPV-positive cervical cancer and head and neck squamous cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• HPV-E6-Specific Anti-PD1 TCR-T Cells

Snippet

Sponsor: Xinqiao Hospital of Chongqing | Conditions: Cervical Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 | Status: COMPLETED